Breaking News
Home / Oncology (page 5)

Oncology

Enfortumab Vedotin Produced Tumor Response Rate of 44% in Patients with the Most Common Type of Advanced Bladder Cancer

BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in …

Read More »

Kite and Humanigen Collaborate to Evaluate Investigational Combination of Yescarta with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

SANTA MONICA, Calif. & BURLINGAME, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). …

Read More »

Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating Lymphocyte Therapy

SAN CARLOS, Calif., May 31, 2019 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced …

Read More »

Data from Phase 3 Study Shows Merck’s Keytruda Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis of the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy, for the first-line treatment of patients with recurrent or metastatic …

Read More »

Roche and GE Launch NAVIFY Tumor Board with Medical Imaging Capabilities to Enable More Personalized Decisions in Cancer Care

Basel, 31 May 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the release of NAVIFY Tumor Board 2.0, the first collaboration product from our partnership with GE Healthcare. Incorporating medical image viewing and storage capabilities with other patient data, the product enables tumour boards – multi-disciplinary teams who …

Read More »

FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

Copenhagen, Denmark; May 30, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (U.S. FDA) granted a Priority Review for the supplemental Biologics License Application (sBLA) for the use of daratumumab (DARZALEX®) in combination with bortezomib, thalidomide and dexamethasone (VTd) as treatment for patients …

Read More »

Lantheus Collaborates with NanoMab to Provide a Novel Biomarker for Clinical Development and Management of Immuno-Oncology Therapies

NORTH BILLERICA, Mass.–(BUSINESS WIRE)–Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, today announced that it has entered into a strategic collaboration and license agreement with NanoMab Technology Limited (“NanoMab”), …

Read More »

Published Study Demonstrates Feasibility of a Blood Test to Predict Disease Progression and Metastasis in Localized Prostate Cancer

SAN DIEGO, May 30, 2019 /PRNewswire/ — Epic Sciences, Inc. announced today the publication of a six-year study demonstrating the clinical applicability of circulating tumor cells (CTCs) to predict prostate cancer progression and metastasis. The study, conducted in collaboration with the University of Michigan utilizing Epic’s CTC technology platform, is …

Read More »

FDA Approves sNDA for Astellas’ Xospata, Adding Overall Survival Data for Patients with Acute Myeloid Leukemia with a FLT3 Mutation

TOKYO, May 30, 2019 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XOSPATA® (gilteritinib) to include final analysis data from …

Read More »

Caris Life Sciences and Debiopharm Partner to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence Transcriptome

IRVING, Texas, May 30, 2019 /PRNewswire/ — Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that it has entered into a strategic collaboration with Debiopharm for the development of a companion diagnostic (CDx) test using its newly-launched Whole Transcriptome …

Read More »